Cited by

• Refractory antimelanoma differentiation-associated gene 5 antibody negative ulcerative dermatomyositis responsive to mycophenolate mofetil.

  Ozer S, Farabi B, Kann R, Atak MF, Shulman K, Marmon S. Ozer S, et al. JAAD Case Rep. 2024 May 21;50:1-3. doi: 10.1016/j.jdcr.2024.05.017. eCollection 2024 Aug. JAAD Case Rep. 2024. PMID: 39036612 Free PMC article. No abstract available.
• Clinical features and outcomes of patients with myositis associated-interstitial lung disease.

  Karampitsakos T, Tzilas V, Papaioannou O, Chrysikos S, Vasarmidi E, Juge PA, Vizirianaki S, Bibaki E, Reppa A, Sidiropoulos P, Katsaras M, Sotiropoulou V, Tsiri P, Koulousousa E, Theochari E, Tsirikos G, Christopoulos I, Malakounidou E, Zarkadi E, Sampsonas F, Hillas G, Karageorgas T, Daoussis D, Kalogeropoulou C, Dimakou K, Tzanakis N, Borie R, Dieudé P, Antoniou K, Crestani B, Bouros D, Tzouvelekis A. Karampitsakos T, et al. Front Med (Lausanne). 2023 Jan 9;9:1096203. doi: 10.3389/fmed.2022.1096203. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36698813 Free PMC article.
• Characterisation of Disease Patterns of Dermatomyositis with Different Initial Manifestations.

  Sun Y, Li DF, Zhang YL, Liang X, Li TF. Sun Y, et al. Int J Gen Med. 2022 Aug 9;15:6519-6528. doi: 10.2147/IJGM.S372658. eCollection 2022. Int J Gen Med. 2022. PMID: 35971527 Free PMC article.
• Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies.

  Nombel A, Fabien N, Coutant F. Nombel A, et al. Front Immunol. 2021 Oct 20;12:773352. doi: 10.3389/fimmu.2021.773352. eCollection 2021. Front Immunol. 2021. PMID: 34745149 Free PMC article. Review.
• Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis.

  Castillo RL, Femia AN. Castillo RL, et al. Ann Transl Med. 2021 Mar;9(5):436. doi: 10.21037/atm-20-5252. Ann Transl Med. 2021. PMID: 33842657 Free PMC article. Review.